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Abstract
Background: In the present study, we demonstrate, in rigorous fashion, that human monocyte-derived
immature dendritic cells (DCs) can efficiently cross-present tumor-associated antigens when co-cultured
with a mixture of human melanoma cells rendered apoptotic/necrotic by γ irradiation (Apo-Nec cells).
Methods: We evaluated the phagocytosis of Apo-Nec cells by FACS after PKH26 and PKH67 staining of
DCs and Apo-Nec cells at different times of coculture. The kinetics of the process was also followed by
electron microscopy. DCs maturation was also studied monitoring the expression of specific markers,
migration towards specific chemokines and the ability to cross-present in vitro the native melanoma-
associated Ags MelanA/MART-1 and gp100.
Results: Apo-Nec cells were efficiently phagocytosed by immature DCs (iDC) (55 ± 10.5%) at 12 hs of
coculture. By 12–24 hs we observed digested Apo-Nec cells inside DCs and large empty vacuoles as part
of the cellular processing. Loading with Apo-Nec cells induced DCs maturation to levels achieved using
LPS treatment, as measured by: i) the decrease in FITC – Dextran uptake (iDC: 81 ± 5%; DC/Apo-Nec 33
± 12%); ii) the cell surface up-regulation of CD80, CD86, CD83, CCR7, CD40, HLA-I and HLA-II and iii)
an increased in vitro migration towards MIP-3β. DC/Apo-Nec isolated from HLA-A*0201 donors were able
to induce >600 pg/ml IFN-γ secretion of CTL clones specific for MelanA/MART-1 and gp100 Ags after 6
hs and up to 48 hs of coculture, demonstrating efficient cross-presentation of the native Ags. Intracellular
IL-12 was detected in DC/Apo-Nec 24 hs post-coculture while IL-10 did not change.
Conclusion: We conclude that the use of a mixture of four apoptotic/necrotic melanoma cell lines is a
suitable source of native melanoma Ags that provides maturation signals for DCs, increases migration to
MIP-3β and allows Ag cross-presentation. This strategy could be exploited for vaccination of melanoma
patients.
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Dendritic cells (DCs) are able to efficiently capture anti-
gens (Ags) at their immature stage (iDC), process them
and initiate immune responses upon interaction with
lymphocytes [1]. The specialized functions of mature DCs
(mDCs) are essential to start T cell mediated immunity
since they can prime naïve T cells. As DCs take up and
process Ags and in response to various stimuli [2-6] they
undergo a process of maturation and express large
amounts of human leukocyte Ags (HLA) – peptide com-
plexes at their surface. To achieve their function, DCs
must arrive into the lymph nodes in response to several
chemoattracting signals that bind specific cell surface
receptors expressed by DCs during the maturation proc-
ess, such as CCR7 (CC chemokine receptor) [7]. Once
DCs have arrived into secondary lymphoid organs, they
can stimulate naïve T cells [8].
A common strategy used for vaccine preparation is to load
DCs with exogenous peptides from tumor associated Ags
(TAAs) on empty HLA class I molecules [9-11]. This
approach, however, has the limitations of peptide restric-
tion to a given haplotype and the induction of responses
to only one or few defined Ags. In order to use a broader
spectrum of known and yet unknown Ags for DCs load-
ing, the approach of whole tumor cells is preferred. We
and others have demonstrated that when murine DCs that
had phagocytosed apoptotic B16 melanoma cells were
used as vaccines, they were able to induce an effective,
long-term protection against challenge with live B16 cells
[12,13].
Since the induction of CD8+ cytotoxic T lymphocytes
(CTLs) appears to play a central role in the process of pro-
tective immunity, only cross-presentation of tumor Ags
acquired from whole tumor cells would confer effective
antitumor immunity. Several authors have demonstrated
in murine models [14,15] and in humans [16]. that when
DCs engulf apoptotic cells, Ags can be cross-presented for
the generation of HLA class I/peptide-complexes, allow-
ing the induction of specific CTLs. However, some con-
flicting findings have been reported in the human, such as
the lack of DCs maturation upon phagocytosis of apop-
totic cells [17-19], so the fate and immunogenic potential
of DCs that have internalized melanoma apoptotic cells
or their debris remain an open issue. Several studies have
used tumor cells virally transduced with TAAs or tumor
cells apoptotized after infection with recombinant viruses
encoding melanoma associated Ags [20-23] but few of
these have evaluated the specific cross-presentation of
native-melanoma Ags present in apoptotic tumor cells.
While we were writing this manuscript, Palucka et al [24]
published the results of a phase I clinical trial of a vaccine
composed of DCs loaded with killed allogeneic
melanoma cells which induced objective clinical
responses and elicited MART-1 specific CD8+T cells in
stage IV patients. Thus, the use of a mixture of apoptotic/
necrotic allogeneic melanoma cell lines as a complex
source of melanoma Ags for DCs cross-presentation could
be further explored to validate and complement these
findings in the clinical setting.
The induction of apoptosis by different methods may pro-
duce a mixture of apoptotic/late apoptotic and/or necrotic
tumor cells that could provide different signals necessary
for DCs maturation as well as for CTL priming [4,25]. To
investigate these points we produced and characterized
human monocyte-derived DCs and co-incubated them
with a mixture of four melanoma cell lines, rendered
apoptotic/necrotic by γ radiation. Upon phagocytosis, we
analyzed DCs maturation through the expression of sur-
face markers and the decrease of the endocytic capacity, in
vitro migration in response to chemokines and, most
importantly, demonstrated their ability to cross-present
native tumor Ags to specific CTLs in vitro.
Methods
Cell lines and clones
Four human melanoma cell lines were used in this study.
Mel-XY1, Mel-XY2, Mel-XY3 and Mel-XX4 were cultured
in melanoma medium (Dulbecco's Modified Eagle
Medium: nutrient Mixture F12 (1:1) supplemented with 2
mM glutamine, 20 nM sodium selenite, 100 µM ascorbic
acid, 0.3 mg/ml galactose, 0.15 mg/ml sodium pyruvate
and 5 µg/ml insulin, 100 IU/ml penicillin, 10 µg/ml strep-
tomycin) plus 10% fetal bovine serum (FBS) (Natocor,
Córdoba, Argentina) in a GMP core facility at the Centro
de Investigaciones Oncológicas-FUCA.
CTL clones (HLA A*0201 restricted) specific for MelanA/
MART-1 (M27: AAGIGILTV) and gp100 (G154:
KTWGQYWQV) Ags were expanded in RPMI medium in
14-day cycles by using 30 ng/ml anti-CD3 antibody (OKT-
3, BD Biosciences) and serial 300 UI/ml IL-2 (Chiron BV,
Amsterdam, Netherlands) every 3 days plus 10% heat-
inactivated AB human serum and antibiotics [26]. Cell
lines were periodically tested to be mycoplasma-free.
Preparation of tumor apoptotic/necrotic cells
Apoptotic/necrotic tumor cells (Apo-Nec cells) were pre-
pared as a batch of four cell lines from master cell banks
after safety testing for mycoplasma, viruses and bacteria.
The complete HLA haplotype of the four melanoma cell
lines that compose Apo-Nec cells is: MEL-XY1: A*0201,
A23; B18, B37; DR7, DR11, DR52, DR53; MEL XY2: A30,
A33; B18, B65; DR1, DR1; MEL-XY3: A*0201, A23; B18,
B18; DR11, DR13, DR52 and MEL-XX4: A24 (9), A33
(19); B18, B65 (14); DR1, DR11. All cell lines express
Tyrosinase, MAGE 3, MelanA/MART-1 (except MEL-XX4Page 2 of 13
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PCR and/or immunocytochemistry (unpublished
results). After gamma irradiation at 70 Gy (Siemens Lineal
Accelerator, Instituto Alexander Fleming, Buenos Aires,
Argentina), the cells were frozen (50% DMEM, 40%
human albumin and 10% DMSO) in liquid nitrogen until
use. Cells were then thawed and plated in melanoma
medium plus 10% FBS to complete the apoptotic process.
After 72 hs the cells were detached from the flasks,
washed, counted and resuspended in fresh serum-free
AIM-V™ Medium (Therapeutic grade, GIBCO, Invitrogen
Corporation, Grand Island, N.Y). Apoptosis and necrosis
were assessed by Annexin-V and Propidium iodide (PI)
binding (Annexin-V apoptosis detection kit, BD Bio-
sciences, San José, CA) and Flow Cytometric (FACS) anal-
ysis (FACSCalibur, BD Biosciences, San José, CA). A soft
agar clonogenic assay performed in sextuplicate (1.5 × 104
cells/well) was used to test that irradiated cells have lost
their proliferation ability compared to non-irradiated
control cells [27].
Generation of DCs from monocytes
DCs were generated from buffy-coats or leukapheresis
products obtained from healthy donors at the Hemother-
apy Department of the Instituto Alexander Fleming.
Peripheral blood mononuclear cells (PBMCs) were puri-
fied by Fycoll-Hypaque density centrifugation. PBMCs
were resuspended in AIM-V medium and allowed to
adhere to 0.22 µm filter-capped culture flasks (TPP, Ger-
many). After 2 hs at 37°C, the non-adherent cells were
removed, and adherent monocytes were subsequently cul-
tured for 5 days in AIM-V supplemented with 800 U/ml
rhuGM-CSF (kindly provided by Dr. Esteban Corley, PC-
Gen, Buenos Aires, Argentina) and 50 ng/ml IL-4 (Pepro-
tech, Mexico). Phenotypic changes were monitored by
light microscopy and FACS. To induce control DCs matu-
ration, 2 µg/ml LPS (Lipopolysaccharide from E. coli J5,
Sigma, St. Louis, CA) was added and the cells were further
cultured for 48 hs.
DCs phenotype
Characterization of DCs phenotype was performed at the
immature state (iDCs) and after Apo-Nec phagocytosis by
staining 5 × 105 cells with fluorochrome-labeled antibod-
ies (Abs) against CD14, CD11c, CD1a, HLA-DR/DP/DQ
(HLA-II), CD80, CD86, CD83, CD40, HLA-ABC (HLA-I)
and CCR7 (BD Biosciences, San Jose, CA), and FACS anal-
ysis was performed with CELLQuest software (Becton
Dickinson, San Jose, CA). The corresponding isotype-
matched controls used were FITC IgG1, FITC IgG2a and
PE Rat IgG2a, (BD Biosciences, San Jose, CA.) Also, to ana-
lyze CD83 expression in double-positive PKH26/PKH67
DCs, we used an unlabeled anti-CD83 mAb (IgG1) and
the corresponding isotype matched control, revealed with
an anti-mouse IgG1-PerCP (BD Biosciences, San José,
CA).
FITC-dextran uptake
DCs endocytosis was evaluated by incubating 1 × 106 cells
with 1 mg/ml FITC-dextran (FITC-Dx) (Sigma, St Louis,
CA) for 30 min at 37°C. After washing with Phosphate
Buffered Saline, cells were analyzed by FACS. Controls
included tubes incubated with FITC-Dx at 4°C to inhibit
the endocytic process and a basal uptake performed at 0
time point. Uptake was quantified by FACS analysis
(10,000 cells per point).
DCs phagocytosis of apoptotic/necrotic tumor cells
Apo-Nec cells (72 hs after irradiation plus culture) were
co-cultured with iDCs (five days culture) at different ratios
(1:1, 2:1 and 3:1) in fresh AIM-V medium for different
time points. In some experiments DCs were dyed red with
PKH26 and Apo-Nec cells were dyed green with PKH67-
GL (Sigma, St. Louis, CA). After co-culture, FACS analysis
was performed and DCs phagocytosis of Apo-Nec cells
was defined by the percentage of double-positive cells.
Appropriate controls were performed to set the cytometer
for each color. A control for non-phagocytic binding of
Apo-Nec cells to DCs was set by incubating the cells at
4°C for the same time points.
in vitro DCs migration
DCs migration was assessed in vitro before and after co-
culture with Apo-Nec cells, using a 48 wells chemotaxis
chamber (AP 48 Neuroprobe Inc., Gaithersburg, MD). In
the lower compartment, 10 ng/ml MIP-1α or MIP-3β
(Peprotech, Rocky Hill, NJ, USA) were placed diluted in
RPMI. Also, random migration was assessed placing RPMI
in the lower chamber. DCs were seeded in the upper
chamber (3 × 104 DCs/well) in RPMI. Between the upper
and lower chamber a 5 µm pore polycarbonate mem-
brane (Neuroprobe, Inc., Bethesda, MD) was placed. After
90 min at 37°C, the cells in the upper face of the mem-
brane were scrapped out and the migrating cells adhered
to the lower face of the membrane were stained with
Giemsa. Membranes were air-dried, mounted onto a glass
slide with Canadax and the cells were counted under the
microscope. Five medium-power (400×) fields/well and 3
wells/condition were analyzed. Statistical analysis was
performed using Student's t-Test.
Electron microscopy
The phagocytic process was also studied by electron
microscopy. Co-cultured samples were fixed at different
time points with 2.5% glutaraldehyde in 0.1 M phosphate
buffer pH 7.4, and then post-fixed in 1% OsO4, washed
twice with distilled water and contrasted with 5% uranyl
acetate for 2 hs. After washing and dehydratation, samples
were embedded in Durkupan. Ultrathin slices (70–90Page 3 of 13
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Reynold's lead citrate. Grids were analyzed under a trans-
mition electron microscope Zeiss 109. Alternatively, to
obtain whole-cell pictures, ultrathin slides (0.5 µm) were
obtained in a ultramicrotome (Reichert-Jung), stained
with 0.4% toluidine blue in 0.1 M carbonate buffer pH
7.4, mounted in Durkupan and analyzed under light
microscopy (1000× magnification). Pictures were
obtained with a Sony Cybershot Digital camera (5 meg-
apixels) and images were further processed with Adobe
Photoshop 6.0.
in vitro cross priming assay – IFN-γ secretion
CD14+ monocytes were purified to 98% from a HLA
A*0201 donor using anti-CD14 microbeads (Miltenyi
Biotec, Germany) and were differentiated to iDCs by 5
days culture as described above. iDCs (6 × 105) were
loaded with Apo-Nec cells (2 × 105) for 6, 12, 24 and 48
hs and incubated overnight with MelanA/MART-1 or
gp100 specific CTL clones (2 × 105 cells) in 1 ml AIM-V
medium. IFN-γ secretion to the supernatant was deter-
mined in triplicate by ELISA (OptEIA IFN-γ, Pharmingen
BD Biosciences, San Diego, CA) according to the manu-
facturer's suggestions. A calibration curve was performed
for each experiment and the sample concentration was
calculated by log-log regression analysis using Cembal 2.2
software. Controls for this experiment included DCs
loaded for 3 hs at 37°C with 20 µg/ml MART-1 or gp100
peptides plus 3 µg/ml β2-microglobulin, Ag-expressing
live melanoma cell lines HLA A*0201 positive (positive
controls) or DCs loaded with the non-specific peptides
and Ag-expressing live melanoma cell lines HLA A*0201
negative (negative controls). G154 and M27 clones were
also incubated with Apo-Nec cells and Apo-Nec Mel-XY2
(HLA*0201 negative, MelanA/MART-1 positive), and DCs
alone.
Measurement of intracytoplasmatic IL-10 and IL-12 
cytokines
DCs were cocultured with Apo-Nec cells in a 3:1 ratio after
labeling with PKH26 and PKH67 respectively, as
described above. At 6, 12, 24 and 48 hs post coculture
intracellular cytokines were accumulated by additional 8
hs-treatment with Brefeldin A (Golgi Plug, BD Bio-
sciences, San José CA). After that, the cells were permeabi-
lized with 0.05% saponin and stained with anti-IL10 (rat
IgG2a)-APC and anti-IL-12 (p40–p70, mouse, IgG1)-
PerCp (BD Biosciences, San José, CA). Isotype matched
controls were also included. For FACS analysis the dou-
ble-stained PKH26/PKH67 population was gated and the
cytokines were evaluated in a four-color experiment. DC/
Apo-Nec cells were compared to non-co-cultured DCs and
Apo-Nec cells at each time point.
Results
Gamma-irradiation induced apoptosis of melanoma cell 
lines
We first tested exposure of the mixture of melanoma cell
lines to different gamma irradiation doses (50, 70 and
100 Gy) to induce apoptosis. 50 Gy irradiation was
enough to completely suppress the clonogenic capacity in
the soft agar assay (0/15,000 colony/cells) for each
melanoma cell line tested (not shown). When cells were
irradiated at 70 or 100 Gy, no significant differences were
observed in the degree of apoptosis/necrosis induced
(data not shown). We have chosen to irradiate cells at 70
Gy and tested different incubation times after irradiation
(24, 48, 72 and 96 hs) in order to complete the apoptotic
process. In Figure 1 we observe that non-irradiated
melanoma cells contained 6–9% early apoptotic cells
characterized by Annexin-V+/PI- staining (lower right
quadrant). After irradiation at 70 Gy and 72 hs culture,
45–53% early apoptotic cells were obtained (Figure 1B,
lower right quadrant). Necrotic cells stained with both
Annexin-V and PI increased from 7.5% in non-irradiated
cells to around 15% in irradiated cells, reflecting necrosis
secondary to apoptosis (upper right quadrants). Thus,
irradiated melanoma cells are defined as Apo-Nec cells in
all the experiments that follow.
Generation and characterization of DCs
To avoid deviation of the immune response to FBS-
derived Ags, a serum-free culture protocol for in vitro gen-
eration of human DCs from PBMCs was developed. We
obtained 5 × 106 DCs from 1 × 108 freshly plated PBMCs,
after depletion of lymphocytes, which did not adhere to
plastic culture flasks, in the presence of rhGM-CSF and IL-
4. When cryopreserved PBMCs or leukapheresis products
Gamma irradiation of a mixture of melanoma cell lines induced apoptosis and necrosis (Apo-Nec cells)Fig re 1
Gamma irradiation of a mixture of melanoma cell 
lines induced apoptosis and necrosis (Apo-Nec cells). 
A mixture of four melanoma cell lines were cultured for 72 
hs, either unirradiated (A) or after gamma irradiation at 
70Gy (B) and stained with annexin V-FITC and PI. Early apop-
totic cells were defined as annexin V-FITC+/PI-, while 
necrotic cells were double-positive. A representative experi-
ment is shown.Page 4 of 13
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lower (3 × 106 DCs from 1 × 108 MN cells).
On day 5, aggregates of cells with the typical morpholog-
ical features of DCs were harvested and phenotypically
characterized. Control mDCs were obtained by adding 2
µg/ml LPS on day 5 and further incubating for 48 hs. Mor-
phological changes during DCs maturation were observed
by light microscopy and confirmed by FACS.
iDCs efficiently phagocyte Gamma irradiation induced 
apoptotic/necrotic melanoma cells
PKH26 red-labeled DCs were co-cultured with PKH67
green-labeled Apo-Nec cells (Figure 2A). After 48 hs
phagocytosis was calculated as the percentage of double-
positive cells, gated into the red-labeled population
(DCs). At 37°C, 70% of DCs have phagocytosed Apo-Nec
cells (Figure 2B) when they were co-cultured in a 3:1
DCs:Apo-Nec cell ratio. In these experiments non phago-
cytic Apo-Nec cells adherence to DCs was scarce since only
6% double-positive DCs were observed when labeled cells
were co-cultured at 4°C for 48 hs to inhibit active DCs
phagocytosis (Figure 2C). It is important to mention that
although Apo-Nec cells were counted as entire cells, apop-
totic bodies derived from the tumor cells were also
present, representing two to three times the number of
entire cells in the mixture (not shown).
Apo-Nec cells phagocytosis by iDC was further confirmed
at different time points of co-culture in ultra-thin slices
stained with toluidine blue and analyzed by electron
microscopy. As shown in Figure 3, at 6 hs DCs had already
engulfed Apo-Nec cells or apoptotic bodies and by 12–24
hs digested cellular material was seen inside large vacu-
oles. By 48–72 hs DCs returned to their normal size and
empty residual vacuoles were frequently observed.
Phagocytosis of apoptotic/necrotic melanoma cells 
induces DC maturation
In order to stimulate naïve T cells, DCs must become
mature increasing the expression of HLA Class I and Class
II molecules and of co-stimulatory signals at the cell sur-
face necessary to trigger T cell priming. iDCs and DCs co-
cultured with Apo-Nec cells (DC/Apo-Nec) were pheno-
typically characterized by immunofluorescence. iDCs and
DC/Apo-Nec were CD14-, CD11c+ and CD1a+ (Figure
4A). As observed in Figure 4B, phagocytosis of Apo-Nec
cells induced DCs maturation similarly to LPS-induced
DCs maturation, compared to iDCs. After 48 hs of Apo-
Nec cells phagocytosis a marked increase in the expression
of HLA class I and II, as well as of CD40, CD80 and CD86
co-stimulatory molecules on DCs was observed. Also,
DCs maturation was evidenced by an increment in CD83
expression. In order to specifically analyze maturation of
DCs that have phagocytosed Apo-Nec cells a three-color
experiment was performed co-culturing red-labeled DCs
(PKH26) with green-labeled Apo-Nec cells (PKH67) for
48 hs and then incubating the cells with PerCp labeled
anti-CD83. When the double-positive PKH26/PKH67
population was gated, 55% of the cells were CD83+
(Mean: 40) compared to iDCs (13.8%, Mean: 22.8), indi-
cating that DCs that have incorporated Apo-Nec cells are
indeed up-regulating CD83 at the cell surface (not
shown). Non-specific binding of antibodies to dying cells
was ruled out in every experiment since anti-DCs markers
binding to isolated Apo-Nec cells was less than 5% or
absent (not shown).
DCs maturation was also evaluated by the decrease of DCs
endocytosis after Apo-Nec cells phagocytosis (Figure 4C).
FITC-Dx endocytosis was maximal in iDCS, 99 ± 5%
uptake (Mean: 224), decreased to 31 ± 3% (Mean: 19) in
LPS-maturated DCs and to 33 ± 5% (Mean: 11) in DC/
Apo-Nec cells.
DCs phagocytosis of Apo-Nec cellsFigure 2
DCs phagocytosis of Apo-Nec cells. DCs were labeled red with PKH26 and Apo-Nec cells were labeled green with 
PKH67 and were analyzed by FACS without co-cultured (A). After coculture at 37°C for 48 hs at a 3:1 ratio (B) cells were ana-
lyzed by FACS. As a control cells was incubated for 48 hs at 4°C (C). The red population was gated and the double-positive 
phagocytic DCs were calculated as % in the upper right quadrants.Page 5 of 13
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Photomicrographs of DCs, Apo-Nec cells and the phagocytic process at different time pointsFigure 3
Photomicrographs of DCs, Apo-Nec cells and the phagocytic process at different time points. A – Characteristic 
morphologies of monocyte-derived iDC (left) and mDC (LPS-treated) (right) are shown under phase contrast microscopy 
(original magnification: 1000×). B – Electron microscopy of an apoptotic body (Apo-Nec sample) showing chromatin condensa-
tion; original magnification: 8000×. C – Representative pictures of the phagocytic process at 0, 6, 12, 24, 48 and 72 hs. In order 
to observe whole cells ultrathin slices (0.5 µm) stained by Toluidine blue were analyzed as described under methods. An Apo-
Nec cell and a DC are indicated (upper and lower arrows, respectively). Original magnification: 1000×. D – Detail of a phago-
cytic DC observed under electron microscopy (4000×) showing digested material at higher magnification (10,000×).
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Maturation of DCs after Apo-Nec cells phagocytosisFig e 4
Maturation of DCs after Apo-Nec cells phagocytosis. A – DCs phenotype was studied before (iDCs) and after cocul-
ture with Apo-Nec cells (DC/Apo-Nec) analyzing CD14, CD11c and CD1a expression as described under Methods. In each 
case isotype-matched controls were performed. B – DCs marker expression of iDCs, LPS-treated DCs and DC/Apo-Nec. 
Cells were stained with FITC-labeled monoclonal antibodies as described under Methods and evaluated by FACS. Grey histo-
grams represent the corresponding isotype matched control Abs. A representative experiment of six is shown. In each histo-
gram the percentage of positive cells and the mean fluorescence intensity (Mean) are indicated. C – Endocytic activity of iDC, 
control LPS-treated DCs and DC/Apo-Nec were evaluated by the uptake of FITC-Dx as described under Methods. Percentage 
of endocytic DCs and Mean are indicated. A representative experiment of four is shown.
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express CCR7 and migrate towards MIP-3 beta in vitro
DCs migration to lymph nodes is crucial to trigger T lym-
phocyte priming. MIP-3β chemokine drives the homing
of mDCs to the lymph node and interacts specifically with
its receptor CCR7 expressed on the cell surface. iDCs
expressed low levels of CCR7 (7%, Mean: 9) but increased
its expression after Apo-Nec phagocytosis (90%; Mean:
18) or LPS maturation (35%, Mean: 13) (Figure 5). We
observed that iDC migrated to MIP-1α but did not
respond to MIP-3β (Figure 5A); on the contrary DC/Apo-
Nec and DC + LPS migrated to MIP-3β but failed to
respond to MIP-1α (Figure 5B and 5C). Thus, DC/Apo-
Nec cells express MIP-3β receptor CCR7 and are able to
migrate in response to MIP-3β, potentially allowing their
homing to lymph nodes.
DCs loaded with apoptotic/necrotic melanoma cells cross-
present MelanA/MART-1 and gp100 Ags to specific T 
CD8+ cells
An important issue in this work was to assess if
melanoma-associated Ags present in the Apo-Nec cells
mixture (native Ags) could be cross-presented to specific
CTLs after DCs phagocytosis. We analyzed IFN-γ secretion
by specific CD8+T clones for MelanA/MART-1 (M27
clone) and gp100 (G154 clone) after overnight stimula-
tion with DC/Apo-Nec cells. As observed in Figure 6A and
6B, DC/Apo-Nec co-cultured with the CTL clones effi-
ciently induced IFN-γ secretion as soon as 6 hs and up to
48 hs after phagocytosis, evidencing cross-presentation
for both Ags. For MelanA/MART-1 Ag we also observed
IFN-γ secretion after incubation with DCs loaded with
Apo-Nec HLA-A*0201 negative MelanA/MART-1+ cells
(Mel-XY2 cell line) clearly demonstrating cross-presenta-
tion for this Ag (Figure 6B). Controls for this experiment
were performed, showing specific HLA-A*0201-restricted
response using either DCs loaded with the corresponding
peptides or CTL stimulation with live HLA-A*0201 posi-
tive gp100+ MelanA/MART-1+ melanoma cells (Mel-XY3)
(Figure 6A and 6B) but lack of response using live MEL-
XY2 cell line or with MelanA/MART-1 peptide for G154
clone or gp100 peptide for M27 clone. Mel-XY3 (HLA-
A*0201 positive cell line) was rendered Apo-Nec by γ irra-
diation and also assayed for CTL priming, however, it only
induced IFN-γ secretion by the CTL clones at short times
after irradiation and culture (6–24 hs) (data not shown).
After 48–72 hs of culture, when HLA-A*0201 positive
Apo-Nec cells have completed the apoptotic-necrotic
process, they failed to present both Ags to CTLs (Figure 6A
and 6B, Apo-Nec bars). We observed that HLA-A*0201
haplotype expression was progressively lost in apoptotic/
necrotic Mel-XY3 cells after gamma irradiation, only
remaining 15–17% HLA-A*0201 positive cells (Mean:
16.7) 48–72 hs post irradiation (Figure 6C). Thus, 72 hs
after irradiation Apo-Nec melanoma cells are no longer
able to activate CTLs by themselves but may be used as a
source of Ags for efficient cross-presentation after DCs
phagocytosis and processing.
Evaluation of Intracytoplasmatic IL-10 and IL-12
The balance between IL-10 and IL-12 in DC/Apo-Nec cells
was quantitated by FACS at different time points after
phagocytosis followed by 8 hs-treatment with Brefeldin A
to accumulate intracytoplasmic cytokines. As shown in
CCR7 expression and in vitro DCs migration in response to MIP-1α and MIP-3βFigure 5
CCR7 expression and in vitro DCs migration in 
response to MIP-1α and MIP-3β. CCR7 expression (left 
panel) was analyzed by FACS in iDCs (A), LPS-treated DCs 
(B) and DC/Apo-Nec (C). Grey histograms represent the 
corresponding isotype matched control Ab. In each histo-
gram the percentage of positive cells and the Mean are indi-
cated. In vitro migration in response to MIP-1α and MIP-3β 
was evaluated (right panel) for iDC, LPS-treated DCs and 
DC/Apo-Nec cells as indicated. A control for random migra-
tion was done using RPMI medium. The number of migrating 
cells was calculated as the mean ± SD of cells counts in five 
medium-power (40×) fields/well performed in triplicate. A 
representative experiment of three is shown *p < 0.05 (Stu-
dent's t-Test).Page 8 of 13
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of co-culture 30.8% of DC/Apo-Nec cells are induced to
produce pro-inflammatory IL-12. Double-positive cells,
producing IL-10 and IL-12, were 27.8% at 24 hs. After 56
hs of co-culture only 10% of the cells produced IL-12
(data not shown). For IL-10 instead, 81.6% of iDCs con-
tained intracytoplasmatic cytokine and this did not signi-
ficatively change after Apo-Nec cells phagocytosis. Apo-
Nec cells were negative for both intracellular cytokines
measured under the same experimental conditions.
Discussion
There is now considerable experimental evidence that
dying cells are capable of transferring Ags to the immune
system for the induction of T cell immunity [19,28,29].
Albert et al first demonstrated in the murine model that
apoptotic material could be processed and cross-pre-
sented by DCs to stimulate specific HLA-restricted CD8+
T cells [30]. In this study, the use of whole apoptotic/
DC/Apo-Nec cross-present MelanA/MART-1 and gp100 Ags to specific T CD8+ cellsFigure 6
DC/Apo-Nec cross-present MelanA/MART-1 and gp100 Ags to specific T CD8+ cells. Overnight IFN-γ secretion 
from G154 clone specific for gp100 (A) and M27 clone for Melan A/MART-1 (B) Ags after different stimuli (indicated in the left 
side) was measured by ELISA as described under Methods. To allow cross-presentation for this experiment, DCs were 
obtained from an HLA-A*0201 donor and monocytes were purified by anti-CD14 magnetic separation as described under 
methods. For DC/Apo-Nec cells different time points after co-culture were studied. Results are the mean of triplicate determi-
nations. (C) Expression of HLA-A*0201 in MART-1+ cell line (Mel-XY3) at different times after γ irradiation and culture was 
measured as described under Methods.
Measurement of intracytoplasmatic IL-10 and IL-12 in DC/Apo-N c cellsFigure 7
Measurement of intracytoplasmatic IL-10 and IL-12 
in DC/Apo-Nec cells. In a four color experiment, intracy-
toplasmatic IL-10 and IL-12 cytokines were measured by 
FACS in iDCs (A) or DC/Apo-Nec (B) as described under 
Methods. Cells were labeled red (iDCs) and green (Apo-Nec 
cells) and after phagocytosis only the double-labeled popula-
tion (DC/Apo-Nec cells) was analyzed with APC-anti IL-10 
and PerCP IL-12 Abs after 8 hs treatment with Brefeldin A. 
10,000 events per point were analyzed.Page 9 of 13
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tage of maturation signals delivered by necrotic cells as
proposed by Gallucci et al [31] and the optimal Ag
processing and presentation in HLA class I and class II
molecules by DCs [32] of a vast repertoire of known as
well as yet unknown Ags from apoptotic cells for the
induction of anti-tumor immune responses. Some contro-
versy has arisen since several authors found that the
uptake of pure or early apoptotic tumor cells did not
induce proper DCs maturation [17,18]. However, these
studies differ from the current one in several aspects: i) we
used a mixture of four apoptotic/necrotic melanoma cell
lines expressing several native melanoma-associated Ags
instead of the single cell line approach or virally trans-
duced tumor cells expressing exogenous Ags [21,22], ii)
we used serum-free medium instead of FCS or autologous
serum to generate monocyte-derived DCs [17], iii) the
method used for tumor Ag preparation consists in gamma
irradiation (70 Gy) and 72 hs culture in melanoma
medium containing FBS as compared to higher energy
radiation and culture in serum free-medium (producing
mainly necrotic cells), UVB exposure or apoptosis
induced by viral infection or by Fas pathway [17,33,34].
Previous reports [17,18] showed that early apoptotic
melanoma cells or pure apobodies failed to induce mDCs,
and either TNF-α, Poly I:C or cytokine cocktails were nec-
essary to achieve DCs maturation and Ag presentation. In
our case, phagocytosis of the mixture of melanoma cell
lines used to load iDCs was enough to generate mDCs
without addition of other stimuli. According to the results
reported by Sauter et at [32] we took advantage of DCs
maturation induced by necrotic tumor cells present in the
mixture of Apo-Nec cell lines, as well as DCs ability of
antigen processing and cross-presentation for CTL prim-
ing due to the apoptotic cells.
Using this particular melanoma cell lines mixture we
wanted to address the question if the uptake of Apo-Nec
cells could allow native TAAs to be processed to peptides
by iDCs, mDCs and cross-present them to specific CTLs.
As we have shown here, high levels of IFN-γ were secreted
by M27 and G154 CTL clones after DC/Apo-Nec stimula-
tion and, more importantly, M27 clone was also stimu-
lated after incubation with DCs that have phagocytosed
HLA-A*0201 negative MelanA/MART-1+ gp100+ Apo-Nec
cells. This results clearly demonstrated that DCs have
processed MelanA/MART-1 Ag taken up from the tumor
cells and presented it to M27 clone in their own HLA-
A*0201 context. As early as 6 hs after DCs loading with
Apo-Nec, these cells could efficiently induce IFN-γ release,
and we were able to measure CTL cross-presentation even
72 hs post DC/Apo-Nec co-culture. Several authors have
identified gp100 as a regression Ag, since the induction of
anti-gp100 immunity correlated with the regression of
documented metastases in melanoma [25,35]. Besides,
anti-MelanA/MART-1 CD8+T lymphocytes have also been
detected in melanoma patients by tetramer staining and
ELISPOT, correlating with clinical outcome and regres-
sions [36]. Labarriere et al [18] reported that the use of
purified melanoma apoptotic bodies to load DCs plus
maturation with cytokines, efficiently cross-primed CTLs
specific for NA-17A Ag but not for MelanA/MART-1 Ag.
The authors could not detect MelanA/MART-1 epitopes in
apobodies using a MelanA/MART-1 specific mAb. In our
case, not only DCs matured after phagocytosis of Apo-Nec
cells but the induction of IFN-γ secretion by a CTL clone
specific for MelanA/MART-1 peptide was found.
Thus, our results suggest that a vaccine such as DC/Apo-
Nec has the potential to initiate an immune response spe-
cific for MelanA/MART-1 and gp100 Ags and probably for
other Ags expressed by these cells. Recently, Palucka et al
[24]. have assayed in a phase I clinical trial a vaccine com-
posed of DCs loaded with killed allogeneic melanoma
cells demonstrating objective clinical responses and
MART-1 specific CD8+T cell immunity. However, in this
study the authors used a single HLA-A*0201 negative all-
ogeneic melanoma cell line killed after a combination of
TNF treatment, γ irradiation and culture in serum-free
medium, plus the addition of CD40L to activate DCs. Our
results further support the use of apoptotic/necrotic allo-
geneic tumor cells as a complex source of multiple
melanoma native Ags to load DCs and show that a good
maturation signal could be obtained with this particular
mixture of melanoma cells, which also allows the cross-
presentation of melanoma Ags to specific CTLs.
As we have demonstrated here, cross-presentation for
MelanA/MART-1 and gp-100 Ags was achieved by DCs
that have phagocytosed Apo-Nec cells but not by Apo-Nec
cells themselves, since Apo-Nec cells (mixture) or HLA-
A*0201 positive Apo-Nec cells (MEL-XY3 irradiated cells)
were not able to induce INF-γ secretion separately. We
have also observed that Apo-Nec cells progressively lost
their HLA-A*0201 surface expression after irradiation and
that their ability to present MelanA/MART-1 and gp100
peptides to CTLs decreased concomitantly (not shown).
These results suggest that Apo-Nec cells are not presenting
the peptides to CTLs by themselves but, after their phago-
cytosis, processed peptides are being cross-presented to
CD8+ T cells by DCs. A recent report by Blanchére et al.
[37] suggested in a murine model that apoptotic cells may
be critical in processing Ags for cross-presentation, in
essence by pre-selection of immunologically important
antigenic determinants. In this view, our results in the
human setting further support this hypothesis, since
tumor dying cells (mainly apoptotic cells) can be used as
a source of processed tumor determinants for DCs loading
and cross-presentation to CTLs. Furthermore, presenta-Page 10 of 13
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has the potential benefit that presentation via HLA class II
may generate helper epitopes that support the develop-
ment of specific CD4+ lymphocytes that might be impor-
tant for antitumoral immunity. We cannot address if Ag
peptides are being processed into Apo-Nec cells and then
taken up by DCs and presented in the HLA class I context
or if DCs have processed them after Apo-Nec phagocyto-
sis. Besides, tumor-derived exosomes loaded onto DCs
have been shown to trigger MART-1 melanoma Ag cross-
presentation to specific CTLs [38] Although we used
washed Apo-Nec cells resuspended in fresh AIM-V
medium in all experiments and a differential ultracentrif-
ugation of culture supernatants is required to obtain
tumor-derived exosomes, we cannot exclude the contribu-
tion of exosomes that might be released by Apo-Nec cells
during the 48 hs co-culture with DCs. Nevertheless, our
main objective has been to assess if this particular mixture
of Apo-Nec cells (either entire or their fragments/debris
after gamma irradiation) was able to be phagocytosed by
iDCs, induce iDCs maturation, migration and cross-pres-
entation of native tumor peptides to specific CD8+ T cells.
We have also evaluated DC/Apo-Nec cells migration to
MIP-3β as a measure of their potential homing to lymph
nodes. Upon phagocytosis, DCs must reach the lymph
nodes in response to chemokine concentration gradients
such as MIP-3β in order to prime naïve T cells. It was
important to asses if DC/Apo-Nec could respond in vitro
to MIP-3β. We found that like fully mature LPS-treated
DCs, DC/Apo-Nec cells up-regulated MIP-3β receptor
(CCR7) and efficiently migrated in vitro to MIP-3β but not
to MIP-1α. Our results are coincident with those reported
by Hirao et al, who found specific DCs migration to MIP-
3β in vitro and in vivo and CCR7 induction after phagocy-
tosis of UV-treated fibrosarcoma cells [39].
The production of the pro-inflammatory cytokine IL-12
requires two signals: IFN-γ and a maturation signal pro-
vided by CD40 ligation (CD40L) or LPS. Recently, Xu et
al [39,40] have proposed that Toll – like receptor 8 pro-
vides a priming signal for high production of IL-12. Pro-
duction of IL-12 and IL-10 influences DCs maturation
and the induction of a potent immune presentation to T
cells [40,41]. Accordingly, we found that upon phagocyto-
sis of Apo-Nec intracellular pro-inflammatory IL-12 tran-
siently increased while IL-10 did not change in DC/Apo-
Nec cells.
We believe that our results complement the existing
reports about the use of apoptotic and necrotic cells to
load iDCs, and demonstrated that they induce DCs matu-
ration, up-regulate CCR7 allowing their migration to MIP-
3β, and efficiently process native melanoma Ags and
cross-present them to specific CTLs. This particular mix-
ture of apoptotic/necrotic cell lines phagocytosed by iDCs
should be tested as a vaccine for melanoma patients since
it could provide mature melanoma Ag-loaded DCs for
efficient cross-priming to elicit anti-tumor immunity.
Conclusion
We used a mixture of four melanoma apoptotic/necrotic
cell lines as a source of native Ags to load human mono-
cyte-derived iDCs. After phagocytosis, we found that Apo-
Nec cells induced DCs maturation without addition of
further stimuli, increased in vitro migration in response to
MIP-3β chemokine and intracellular IL-12 production.
Most importantly, we demonstrated the ability of DC/
Apo-Nec cells to cross-present native tumor Ags to Ag-spe-
cific CTLs in vitro. We suggest that our results with DC/
Apo-Nec should be explored as a vaccination strategy in
melanoma patients.
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